
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion AS demonstrates a strong financial outlook based on the promising efficacy and safety profile of its lead product, EVX-01, which has shown a 75% objective response rate (ORR) in combination with pembrolizumab, an improvement from 69% reported previously. The accuracy of the company’s AI predictive models, particularly the PIONEER model, has also improved, with 81% of predicted neoantigens proving to be immunogenic, reinforcing Evaxion's leadership in the neoantigen cancer vaccine sector. Moreover, a significant percentage of patients (54%) experienced deepening responses following treatment, showcasing the potential for long-term effectiveness and the transformative impact of Evaxion's proprietary technologies on patient outcomes.
Bears say
Evaxion AS experienced a negative market reaction to their strong data update for the EVX-01 despite the promising developments in their clinical-stage oncology pipeline. The disappointment appears to stem from investors seeking a more definitive indication of EVX-01's contribution to the company's future performance. This uncertainty around product impact highlights a potential risk in the stock's performance relative to the company's projected advancements in immunotherapy.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares